Rigel Pharmaceuticals | RIGL - DEBITO





DEBITO Cambiamento Data
Agenus USD 35.54M 2.34M 2025-03
Amgen USD 54.6B 17M 2025-12
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 366.28M 13.25M 2025-09
AstraZeneca USD 33.92B 4.3B 2026-03
BioMarin Pharmaceutical USD 605.86M 1.62M 2025-12
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Celldex Therapeutics USD 2.34M 285K 2025-12
Daiichi Sankyo JPY 201.14B 99.81B 2025-09
Eli Lilly USD 42.5B 3.6M 2025-12
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Heron Therapeutics USD 149.65M 157K 2024-09
Intrexon USD 0 13.82M 2024-06
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Ligand Pharmaceuticals USD 451M 445.26M 2025-09
MacroGenics USD 37.01M 238K 2025-09
Neurocrine Biosciences USD 415.3M 13.1M 2025-12
Pfizer USD 63.96B 3.11B 2025-12
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sangamo BioSciences USD 0 0 2022-06
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Veracyte USD 39.65M 799K 2025-12